Document is current
Any future updates will be listed below
-
Authors
Isla, D. https://orcid.org/0000-0002-2483-198X
de Castro, J. https://orcid.org/0000-0002-3622-6306
García-Campelo, R.
Lianes, P. https://orcid.org/0000-0002-4976-9246
Felip, E. https://orcid.org/0000-0002-7620-0098
Garrido, P. https://orcid.org/0000-0002-5899-6125
Paz-Ares, L. https://orcid.org/0000-0002-1947-3364
Trigo, J. M.
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
- License Information
-
More Information
Article History
Received: 28 May 2019
Accepted: 17 July 2019
First Online: 31 July 2019
Compliance with ethical standards
:
: The authors would like to disclose the following: Dolores Isla: personal financial interests: consulting and advisory services: Roche, MSD, BMS, Boehringer Ingelheim, Pfizer, Abbvie, Guardant Health, Novartis, Lilly, Astra-Zeneca, Jansen, Sysmex, Blueprint Medicines, Takeda. Speaking, public presentations: Roche, MSD, BMS, Pfizer, Novartis, Boehringer Ingelheim, Rovi. Institutional financial interests: financial support for clinical trials: Roche, MSD, BMS, Takeda, Lilly, Pfizer, Novartis, Pharmamar, Celgene, Sanofi, GSK, Theradex Oncology, BluePrint Medicines. Financial support for contracted research: Guardant Health, Sysmex. Javier de Castro: educational grants: Astra-Zeneca, Boehringer Ingelheim, BMS, MSD, Novartis, Roche. Scientific consulting: Astra-Zeneca, Boehringer Ingelheim, BMS, MSD, Novartis, Pfizer, Roche, Takeda. Rosario García Campelo: consulting, advisory role or speaker’s bureau: Boehringer Ingelheim, BMS, Astra-Zeneca, Roche, MSD. Pilar Garrido: personal financial interests: consulting and advisory services: Roche, MSD, BMS, Boehringer Ingelheim, Pfizer, Abbvie, Guardant Health, Novartis, Lilly, Astra-Zeneca, Jansen, Sysmex, Blueprint Medicines, Takeda. Speaking, public presentations: Roche, MSD, BMS, Pfizer, Novartis, Boehringer Ingelheim, Rovi. Institutional financial interests: financial support for clinical trials: Roche, MSD, BMS, Takeda, Lilly, Pfizer, Novartis, Pharmamar, Celgene, Sanofi, GSK, Theradex Oncology, BluePrint Medicines. Financial support for contracted research: Guardant Health, Sysmex. Enriqueta Felip: Consulting, advisory role or speaker’s bureau: Abbvie, Astra-Zeneca, Blue Print Medicines, Boehringer Ingelheim, BMS, Eli Lilly, Guardant Health, Janssen, Medscape, Merck KGaA, MSD, Novartis, Pfizer, Roche, Takeda, Touchtime. Luis Paz-Ares: Consulting, advisory role or speaker’s bureau: Lilly, MSD, BMS, Roche, Pharmamar, Merck KGaA, Astra-Zeneca, Novartis, Boehringer Ingelheim, Celgene, Servier, Sysmex, Amgen, Incyte, Pfizer, Ipsen, Adacap, Sanofi, Bayer, Blueprint Board Member: Genómica. Research grants to institution: MSD, BMS, Astra-Zeneca, Pfizer. José Manuel Trigo: consulting, advisory role or speaker’s bureau: Astra-Zeneca, Boehringer Ingelheim, BMS, MSD, Takeda. All remaining authors have declared no conflict of interest.
: This study consisted of a survey of expert opinions and no patient data were collected, so no specific independent ethical or research review or approval was necessary.
: For this type of study formal consent is not required.
